Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mersana Therapeutics Inc.

0.3639
+0.00160.44%
Post-market: 0.3637-0.0002-0.05%19:49 EDT
Volume:1.69M
Turnover:604.44K
Market Cap:45.35M
PE:-0.64
High:0.3716
Open:0.3700
Low:0.3500
Close:0.3623
Loading ...

Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at Asco 2025 Annual Meeting

THOMSON REUTERS
·
23 Apr

Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting

GlobeNewswire
·
23 Apr

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
05 Apr

Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress

GlobeNewswire
·
01 Apr

Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates

Simply Wall St.
·
06 Mar

Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts

Simply Wall St.
·
05 Mar

Truist Financial Reaffirms Their Buy Rating on Mersana Therapeutics (MRSN)

TIPRANKS
·
04 Mar

Mersana Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
04 Mar

Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com
·
04 Mar

Mersana Therapeutics’ Viability in Question Amidst Persistent Financial Losses and Funding Challenges

TIPRANKS
·
04 Mar

Q4 2024 Mersana Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
04 Mar

Mersana Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
04 Mar

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
03 Mar

Mersana Therapeutics Q4 EPS $(0.11) Beats $(0.15) Estimate, Sales $16.36M Beat $7.71M Estimate

Benzinga
·
03 Mar

BRIEF-Mersana Therapeutics Q4 EPS USD -0.11

Reuters
·
03 Mar

Mersana Therapeutics Q4 EPS USD -0.11

THOMSON REUTERS
·
03 Mar

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
03 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
03 Mar

BRIEF-Mersana Therapeutics Receives Nasdaq Non-Compliance Notice

Reuters
·
01 Mar

Mersana Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
28 Feb